Abstract
Pharmacodynamic modeling is based on a quantitative integration of pharmacokinetics, pharmacological systems, and (patho-) physiological processes for understanding the intensity and time-course of drug effects on the body. Application of such models to the analysis of meaningful experimental data allows for the quantification and prediction of drug–system interactions for both therapeutic and adverse drug responses. In this chapter, commonly used mechanistic pharmacodynamic models are presented with respect to their important features, operable equations, and signature profiles. In addition, literature examples showcasing the utility of these models to adverse drug events are highlighted. Common model types that are covered include simple direct effects, biophase distribution, indirect effects, signal transduction, and irreversible effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berger SI, Iyengar R (2011) Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med 3:129–135
Levy G (1964) Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects. J Pharm Sci 53:342–343
Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7:362–372
Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510–518
Yates FE (1975) On the mathematical modeling of biological systems: a qualified ‘pro’. In: Vernberg FJ (ed) Physiological adaptation to the environment. Intext Educational Publishers, New York
Wagner JG (1968) Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20:173–201
Friberg LE, Isbister GK, Hackett LP, Duffull SB (2005) The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn 32:571–605
Minematsu T, Ohtani H, Yamada Y, Sawada Y, Sato H, Iga T (2001) Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. J Pharmacokinet Pharmacodyn 28:533–554
Laizure SC, Parker RB (2009) Pharmacodynamic evaluation of the cardiovascular effects after the coadministration of cocaine and ethanol. Drug Metab Dispos 37:310–314
Vage C, Saab N, Woster PM, Svensson CK (1994) Dapsone-induced hematologic toxicity: comparison of the methemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood. Toxicol Appl Pharmacol 129:309–316
Furchgott RF (1955) The pharmacology of vascular smooth muscle. Pharmacol Rev 7:183–265
Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358–371
Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M (2007) Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther 321:598–607
Stroh M, Addy C, Wu Y, Stoch SA, Pourkavoos N, Groff M, Xu Y, Wagner J, Gottesdiener K, Shadle C, Wang H, Manser K, Winchell GA, Stone JA (2009) Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event. AAPS J 11:99–108
Nagashima R, O’Reilly RA, Levy G (1969) Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 10:22–35
Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457–478
Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406–419
Sharma A, Jusko WJ (1998) Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45:229–239
Sharma A, Ebling WF, Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577–1584
Woo S, Krzyzanski W, Jusko WJ (2008) Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol 62:123–133
Sun YN, Jusko WJ (1998) Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87:732–737
Mager DE, Jusko WJ (2001) Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210–216
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713–4721
Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD (2009) Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. J Pharmacokinet Pharmacodyn 36:39–62
Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JH, Huitema AD (2008) PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83:829–839
Soto E, Staab A, Freiwald M, Munzert G, Fritsch H, Doge C, Troconiz IF (2010) Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. Clin Pharmacol Ther 88:660–667
Jusko WJ (1971) Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 60:892–895
Fasanmade AA, Jusko WJ (1995) An improved pharmacodynamic model for formation of methemoglobin by antimalarial drugs. Drug Metab Dispos 23:573–576
Houze P, Mager DE, Risede P, Baud FJ (2010) Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicity. Toxicol Sci 116:660–672
Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko WJ (2004) Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn 31:345–380
Hazra A, Pyszczynski N, DuBois DC, Almon RR, Jusko WJ (2007) Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. J Pharmacokinet Pharmacodyn 34:643–667
Barras MA, Duffull SB, Atherton JJ, Green B (2009) Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. Br J Clin Pharmacol 68:700–711
Jusko WJ, Ko HC, Ebling WF (1995) Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 23:5–8
Acknowledgments
The authors thank Dr. William J. Jusko (University at Buffalo, SUNY) for reviewing this chapter and providing insightful feedback. This work was supported by Grant No. GM57980 from the National Institutes of General Medicine, Grant No. DA023223 from the National Institute on Drug Abuse, and Hoffmann-La Roche Inc.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Felmlee, M.A., Morris, M.E., Mager, D.E. (2012). Mechanism-Based Pharmacodynamic Modeling. In: Reisfeld, B., Mayeno, A. (eds) Computational Toxicology. Methods in Molecular Biology, vol 929. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-050-2_21
Download citation
DOI: https://doi.org/10.1007/978-1-62703-050-2_21
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-049-6
Online ISBN: 978-1-62703-050-2
eBook Packages: Springer Protocols